Similar articles

• Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference.

  Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB; National Psoriasis Foundation. Rosmarin DM, et al. J Am Acad Dermatol. 2010 May;62(5):838-53. doi: 10.1016/j.jaad.2009.05.017. Epub 2009 Nov 24. J Am Acad Dermatol. 2010. PMID: 19932926 Review.
• Ciclosporin in psoriasis clinical practice: an international consensus statement.

  Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, Johnston A, Katsambas A, Lison AE, Naeyaert JM, Nakagawa H, Paul C, Vanaclocha F. Griffiths CE, et al. Br J Dermatol. 2004 May;150 Suppl 67:11-23. doi: 10.1111/j.0366-077X.2004.05949.x. Br J Dermatol. 2004. PMID: 15115441 Review.
• Cyclosporine: what clinicians need to know.

  Koo J, Lee J. Koo J, et al. Dermatol Clin. 1995 Oct;13(4):897-907. Dermatol Clin. 1995. PMID: 8785893 Review.
• Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis.

  Yamauchi PS, Lowe NJ. Yamauchi PS, et al. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S135-8. doi: 10.1016/j.jaad.2005.11.1043. J Am Acad Dermatol. 2006. PMID: 16488328 No abstract available.
• Consensus on the use of cyclosporine in dermatological practice. Italian Consensus Conference.

  Altomare G, Ayala F, Bardazzi F, Bellia G, Chimenti S, Colombo D, Flori ML, Girolomoni G, Micali G, Parodi A, Peris K, Vena GA; Italian Consensus Conference. Altomare G, et al. G Ital Dermatol Venereol. 2014 Oct;149(5):607-25. G Ital Dermatol Venereol. 2014. PMID: 25213388